NFE2L2 and neoplasm: Doses of bardoxolone methyl that increased expression of the classic Nrf2 target gene NQO1 and decreased tumor levels of NF-κB and cyclin D1 were well-tolerated by patients with advanced malignancies in a phase 1 trial (ClinicalTrials.gov ID: NCT00529438) [27].